Skip to main content

Advertisement

SpringerLink
Log in

Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor. Although clinical presentation and brain imaging might be suggestive, histopathological evaluation by means of a brain biopsy is routinely performed to establish the diagnosis. A serum marker indicative of GBM may simplify the diagnostic work-up of patients suspected to having a brain tumor. We prospectively examined 113 patients with newly diagnosed single supratentorial or infratentorial space-occupying brain lesions. Glial fibrillary acidic protein (GFAP) levels were determined from venous blood samples via a prototype ELISA assay prior to any invasive procedures. Serum levels of GFAP were correlated with histopathological findings and MRI parameters. GFAP values were significantly higher in GBM patients (n = 33) compared to all other tumors (p < 0.001). A GFAP serum concentration of ≥0.01 µg/L revealed a sensitivity of 85 % and a specificity of 70 % for differentiating GBM from other entities. By applying a GFAP cut-off point of 0.20 µg/L, specificity was maximized (99 %), but sensitivity dropped to 27 %. In GBM patients, serum GFAP values were significantly correlated with tumor volume. GBM patients with high GFAP levels showed more in vivo GFAP expression as well as more necrosis and perilesional edema compared to GBM patients having low or non-detectable GFAP levels. GFAP serum concentrations differentiated between patients with GBM and patients with cerebral mass lesions of other entities with a moderate diagnostic accuracy. Serum GFAP levels in GBM patients were positively correlated with tumor volume and histopathological tumor characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899

    Article  PubMed  CAS  Google Scholar 

  2. Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y, Nakano T (2015) Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme. Anticancer Res 35:1229–1235

    PubMed  CAS  Google Scholar 

  3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  4. Eng LF (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 8:203–214

    Article  PubMed  CAS  Google Scholar 

  5. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25:1439–1451

    Article  PubMed  CAS  Google Scholar 

  6. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380–384

    Article  PubMed  CAS  Google Scholar 

  7. Gallego Perez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A (2014) Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer 120:3972–3980

    Article  PubMed  CAS  Google Scholar 

  8. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336–3341

    Article  PubMed  CAS  Google Scholar 

  9. Jung CS, Unterberg AW, Hartmann C (2011) Diagnostic markers for glioblastoma. Histol Histopathol 26:1327–1341

    PubMed  CAS  Google Scholar 

  10. Diaz-Arrastia R, Wang KK, Papa L, Sorani MD, Yue JK, Puccio AM, McMahon PJ, Inoue T, Yuh EL, Lingsma HF, Maas AI, Valadka AB, Okonkwo DO, Manley GT (2014) Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 31:19–25

    Article  PubMed  PubMed Central  Google Scholar 

  11. Foerch C, Niessner M, Back T, Bauerle M, De Marchis GM, Ferbert A, Grehl H, Hamann GF, Jacobs A, Kastrup A, Klimpe S, Palm F, Thomalla G, Worthmann H, Sitzer M (2012) Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem 58:237–245

    Article  PubMed  CAS  Google Scholar 

  12. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR (2013) Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg 119:427–433

    Article  PubMed  Google Scholar 

  13. Yung WK, Luna M, Borit A (1985) Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol 3:35–38

    PubMed  CAS  Google Scholar 

  14. Lyubimova NV, Toms MG, Popova EE, Bondarenko YV, Krat VB, Kushlinskii NE (2011) Neurospecific proteins in the serum of patients with brain tumors. Bull Exp Biol Med 150:732–734

    Article  PubMed  CAS  Google Scholar 

  15. Larsson IM, Wallin E, Kristofferzon ML, Niessner M, Zetterberg H, Rubertsson S (2014) Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. Resuscitation 85:1654–1661

    Article  PubMed  CAS  Google Scholar 

  16. Mayer CA, Brunkhorst R, Niessner M, Pfeilschifter W, Steinmetz H, Foerch C (2013) Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases. PLoS One 8:e62101

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255–268

    Article  PubMed  CAS  Google Scholar 

  18. Harter PN, Bunz B, Dietz K, Hoffmann K, Meyermann R, Mittelbronn M (2010) Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development. Neuropathol Appl Neurobiol 36:623–635

    Article  PubMed  CAS  Google Scholar 

  19. Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP (2014) Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Asian Pac J Cancer Prev 15:10893–10898

    Article  PubMed  Google Scholar 

  20. Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bahr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Husing J, Reifenberger G, Wick W (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 21(9):2057–2064

    Article  PubMed  CAS  Google Scholar 

  21. Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bahr O, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M (2014) Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies. Stereotact Funct Neurosurg 92:129–139

    PubMed  Google Scholar 

  22. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27:1304–1305

    Article  PubMed  CAS  Google Scholar 

  23. Papa L, Silvestri S, Brophy GM, Giordano P, Falk JL, Braga CF, Tan CN, Ameli NJ, Demery JA, Dixit NK, Mendes ME, Hayes RL, Wang KK, Robertson CS (2014) GFAP out-performs S100beta in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J Neurotrauma 31:1815–1822

    Article  PubMed  PubMed Central  Google Scholar 

  24. Petzold A (2015) Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 1600:17–31

    Article  PubMed  CAS  Google Scholar 

  25. Lyubimova NV, Toms MG, Fu RG, Bondarenko YV (2013) Biochemical markers of brain tumours. Klin Lab Diagn 71–72:40–72

    Google Scholar 

  26. Wilhelmsson U, Eliasson C, Bjerkvig R, Pekny M (2003) Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Oncogene 22:3407–3411

    Article  PubMed  CAS  Google Scholar 

  27. Brunkhorst R, Pfeilschifter W, Foerch C (2010) Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings. Transl Stroke Res 1:246–251

    Article  PubMed  CAS  Google Scholar 

  28. Noreen F, Roosli M, Gaj P, Pietrzak J, Weis S, Urfer P, Regula J, Schar P, Truninger K (2014) Modulation of age- and cancer-associated DNA methylation change in the healthy colon by aspirin and lifestyle. J Natl Cancer Inst 106(7):dju161

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kiviniemi A, Gardberg M, Frantzen J, Parkkola R, Vuorinen V, Pesola M, Minn H (2015) Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival. J Neurooncol 124:237–245

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Goethe-University, Frankfurt am Main, Germany

    Julia Tichy, Sabrina Spechtmeyer & Christian Foerch

  2. Dr. Senckenberg Institute of Neurooncology, Goethe-University, Frankfurt am Main, Germany

    Julia Tichy & Johannes Rieger

  3. Neurological Institute (Edinger Institute), Goethe-University, Frankfurt am Main, Germany

    Julia Tichy & Michel Mittelbronn

  4. German Cancer Consortium (DKTK), Heidelberg, Germany

    Michel Mittelbronn

  5. German Cancer Research Center (DKFZ), Heidelberg, Germany

    Michel Mittelbronn

  6. Institute of Neuroradiology, Goethe-University, Frankfurt am Main, Germany

    Elke Hattingen

  7. Department of Neurosurgery, Goethe-University, Frankfurt am Main, Germany

    Christian Senft

  8. Dr. Senckenberg Institute of Neurooncology, Department of Neurology, Goethe-University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany

    Julia Tichy

Authors
  1. Julia Tichy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabrina Spechtmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Mittelbronn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Hattingen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johannes Rieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Senft
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian Foerch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia Tichy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tichy, J., Spechtmeyer, S., Mittelbronn, M. et al. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol 126, 361–369 (2016). https://doi.org/10.1007/s11060-015-1978-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1978-8

Keywords

Search

Navigation